NCT03349619View on ClinicalTrials.gov

Nebulized Resveratrol Plus Carboxymethyl-β-Glucan for Reducing IL-5 in Children With Allergic Rhinitis

PHASE4CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions
Allergic Rhinitis
Interventions
DRUG

Resveratrol plus Carboxymethyl-β-Glucan

Patients in this arm will receive Resveratrol plus Carboxymethyl-β-Glucan, two sprays (100µL/spray) per nostril three times/day for 4 weeks

DRUG

Placebo

Patients in this arm will receive nasal saline solution 0.9%, two sprays per nostril, three times/day for 4 weeks

Trial Locations (1)

90146

Institute of Biomedicine and Molecular Immunology (IBIM) - National Research Council of Palermo, Palermo

All Listed Sponsors
lead

Istituto per la Ricerca e l'Innovazione Biomedica

OTHER

NCT03349619 - Nebulized Resveratrol Plus Carboxymethyl-β-Glucan for Reducing IL-5 in Children With Allergic Rhinitis | Biotech Hunter | Biotech Hunter